Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05445778 · ClinicalTrials.gov registry record · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT05445778: Recruiting Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by AbbVie.
NCT05445778 is a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by AbbVie. The registered enrollment target is 520 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05445778, a Phase 3 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Primary Outcome
Progression-free survival defined as assessed by BICR per RECIST v1.1, defined as the time from date of randomization until BICR-assessed PD or death due to any cause, whichever occurs first
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Mirvetuximab soravtansine plus Bevacizumab
Study Locations (20)
California
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 269573 - Irvine
- Moores Cancer Center at UC San Diego /ID# 269564 - La Jolla
- Kaiser Permanente - Los Angeles Medical Center /ID# 269541 - Los Angeles
- University Of California Irvine Medical Center /ID# 269572 - Orange
- Stanford Women'S Cancer Center /ID# 269552 - Palo Alto
- Kaiser Permanente - Riverside Medical Center /ID# 269539 - Riverside
- Kaiser Permanente Zion Medical Center /ID# 269537 - San Diego
- Kaiser Permanente - San Diego Medical Center /ID# 269540 - San Diego
- Kaiser Permanente - San Marcos Medical Offices /ID# 269542 - San Marcos
- Olive View-Ucla Medical Center /ID# 269584 - Sylmar
- John Muir Health - Walnut Creek Medical Center /ID# 269575 - Walnut Creek
Florida
- Broward General Medical Center /ID# 269577 - Fort Lauderdale
- Regional Cancer Center /ID# 269558 - Fort Myers
- Baptist Md Anderson Cancer Center - Jacksonville - Palm Avenue /ID# 269560 - Jacksonville
- Mount Sinai Medical Center /ID# 269582 - Miami
- Sarasota Memorial Hospital /ID# 269526 - Sarasota
Alabama
- Usa Mitchell Cancer Institute /ID# 269661 - Mobile
Arizona
- Honorhealth Virginia G. Piper Cancer Care Network - Biltmore /ID# 269987 - Phoenix
Georgia
- Northside Hospital /ID# 269660 - Atlanta
Illinois
- Rush University Medical Center /ID# 269583 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2032-05 |
| Phase | Phase 3 |
What NCT05445778 shows while recruiting
NCT05445778 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (28% lower).
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT05445778 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05445778 about?
NCT05445778 is a clinical study titled "Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer". GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expre...
What is the current status of trial NCT05445778?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2023-03-15. Estimated completion is 2032-05.
What conditions does trial NCT05445778 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT05445778?
The interventions under investigation include: Bevacizumab (DRUG), Mirvetuximab soravtansine plus Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT05445778?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05445778 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05445778's enrollment target sits among peer trials
520 47th of 322 higher than 276 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- NCT05908240 · 520 participants · NA
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI